tDCS and Cognitive Training in Active Duty Service Members With Mild TBI: A Pilot Study

Mild Cognitive Impairment Clinical Trial

Official title:

Transcranial Direct Current Stimulation (tDCS) and Cognitive Training to Improve Concentration and Working Memory in Active Duty Service Members Following Mild Traumatic Brain Injury (mTBI): A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04925453
• Other study ID #: NMCSD.2020.0016
• Status: Recruiting
• Phase: N/A
• Start date: January 19, 2021
• Est. completion date: December 2023

Study information

• Verified date: September 2022
• Source: United States Naval Medical Center, San Diego
• Contact: Lars D Hungerford, PhD
• Phone: 619.532.5715
• Email: lars.d.hungerford.ctr[@]mail.mil
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study will evaluate a new approach to cognitive rehabilitation of mild traumatic brain injury (mTBI) using a brain stimulation technique called transcranial direct current stimulation (tDCS). Specifically, we will investigate how tDCS combined with cognitive training improves deficits to attention and working memory in Active Duty Service Members with a history of mild traumatic brain injury (TBI). Measures of attention-related brain activity, neurocognitive assessments, and self-reported clinical outcomes will be used to determine effects of tDCS vs. sham tDCS when paired with a cognitive training intervention. By doing this study, we hope to find a reliable, noninvasive, and efficient method of treating mild TBI cognitive symptoms.

Description:

Objectives: The proposed study will evaluate a new approach to cognitive rehabilitation of mild traumatic brain injury (mTBI) using a brain stimulation technique called transcranial direct current stimulation (tDCS). Specifically, we will investigate how tDCS combined with cognitive training improves deficits to attention and working memory in Active Duty Service Members with a history of mTBI. Measures of attention-related brain activity, neurocognitive assessments, and self-reported clinical outcomes will be used to determine effects of tDCS vs. sham tDCS when paired with a cognitive training intervention. By doing this study, we hope to find a reliable, noninvasive, and efficient method of treating mild TBI cognitive symptoms. Research Plan and Methods: This is a double-blind, randomized, placebo (sham) controlled pilot study. We will recruit 60 Active Duty Service Members who are receiving outpatient services at Naval Medical Center San Diego, with a history of mTBI and reported neurocognitive symptoms related to attention, working memory, and related cognitive processes. Intake will involve a full pre-assessment of symptoms, neurocognitive performance, and an optional MRI scan. Participants will be randomized to either active or sham tDCS. Training/tDCS sessions will occur daily over five consecutive days. Random permuted blocks will be used to ensure exactly equal treatment numbers at certain equally spaced points in the sequence of patient assignment. Post-intervention assessment will include another assessment of symptoms, neurocognitive performance, and an optional MRI scan. Participants will complete assessments of symptoms and neurocognitive performance six-weeks following the post-intervention assessment. Clinical Relevance to TBICoE/Navy Medicine: Aspects of this study will provide insight into a major research gap highlighted in the mission of the Defense and Veterans Brain Injury Center, specifically in identifying/ developing innovative treatments/interventions which promote patient recovery and/or mitigate symptoms after mTBI. Novel, well-tolerated, neuroplasticity-based interventions that can improve attention, concentration, and working memory by targeting the underlying neural dysfunction are needed to improve outcomes and quality of life for Active Duty Service Members affected by neurocognitive weakness and dysfunction following mTBI. If tDCS proves successful in reducing TBI-related symptoms, improving cognition, or enhancing functional recovery, this non-invasive intervention could be implemented within various DoD and VA settings, enhancing recovery, improving quality of life, and bolstering occupational performance.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• (1) Have a remote history mild traumatic brain injury as defined by the VA/DoD clinical practice guidelines(The Management of Concussion/mTBI Working Group, 2016) that is >/= 6 months, and report moderate severity neurocognitive symptoms related to attention, concentration, working memory, or memory based on NSI scores and self-report.
• (2) Are between the ages of 18-55.
• (3) Are stable on any medications for at least 2 weeks at the baseline visit (Visit #1).

Exclusion Criteria:

• (1) Have a history of seizures or epilepsy.
• (2) Have a history of ECT or cortical energy exposure within the past 12 months, including participation in any other neuromodulation studies.
• (3) Have current stimulant dependence.
• (4) Have a diagnosis of intellectual disability or pervasive developmental disorder (i.e. premorbid IQ less than or equal to 70).
• (5) Have any medical condition or treatment other than mild TBI (e.g. stroke, tumor, HIV, moderate-severe TBI), with significant neurological disorder or insults that, based on the Principal Investigator's judgement, would impact risk.
• (6) Diagnosed with current active psychosis or mania.
• (7) Have metallic cranial plates/screws or implanted device,
• (8) Have eczema on scalp or other scalp lesions or skin disorders that may become irritated by stimulation.
• (9) Pregnant individuals and individuals with ferromagnetic metal in their body that would prohibit them from being safe in the MRI will not be excluded from the overall study, but will be excluded from the optional MRI.

Related Conditions & MeSH terms

• Attention Concentration Difficulty
• Attention Impaired
• Brain Concussion
• Brain Injuries
• Brain Injuries, Traumatic
• Brain Trauma
• Cognitive Dysfunction
• Memory Impairment
• Mild Cognitive Impairment
• Mild Traumatic Brain Injury
• Neurocognitive Dysfunction
• Wounds and Injuries

Intervention

Combination Product:
• active tDCS and cognitive training intervention
Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
• sham tDCS and cognitive training intervention
Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.

Locations

Country	Name	City	State
United States	Naval Medical Center San Diego	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
United States Naval Medical Center, San Diego	The Defense and Veterans Brain Injury Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symbol Digit Modalities Test (SDMT)	Standardized neuropsychological assessment measure of visual attention and working memory	Change from Baseline SDMT at 1 week after the intervention.
Primary	Symbol Digit Modalities Test (SDMT)	Standardized neuropsychological assessment measure of visual attention and working memory	Change from Baseline SDMT at 6 weeks after the intervention.
Primary	Symbol Digit Modalities Test (SDMT)	Standardized neuropsychological assessment measure of visual attention and working memory	Change from 1 week post-intervention SDMT at 6 weeks after the intervention.
Primary	Neuropsychological Assessment Battery (NAB) Attention Module	Standardized neuropsychological assessment consisting of 4 subtests to assess visual and auditory attention, working memory, and scanning.	Change from Baseline NAB Attention Module at 1 week after the intervention.
Primary	Neuropsychological Assessment Battery (NAB) Attention Module	Standardized neuropsychological assessment consisting of 4 subtests to assess visual and auditory attention, working memory, and scanning.	Change from Baseline NAB Attention Module at 6 weeks after the intervention.
Primary	Neuropsychological Assessment Battery (NAB) Attention Module	Standardized neuropsychological assessment consisting of 4 subtests to assess visual and auditory attention, working memory, and scanning.	Change from 1 week post-intervention NAB Attention Module at 6 weeks after the intervention.
Primary	Electroencephalogram (EEG)	EEG will be collected to assess neural dynamics during rest and during performance of generalization tasks. The neural dynamics to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands.	Change from Baseline EEG at 1 week after the intervention.
Primary	Electroencephalogram (EEG)	EEG will be collected to assess neural dynamics during rest and during performance of generalization tasks. The neural dynamics to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands.	Change from Baseline EEG at 6 weeks after the intervention.
Primary	Electroencephalogram (EEG)	EEG will be collected to assess neural dynamics during rest and during performance of generalization tasks. The neural dynamics to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands.	Change from 1 week post-intervention EEG at 6 weeks after the intervention.
Primary	Neurobehavioral Symptom Inventory (NSI)	A measure of common post-concussive symptoms rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to more severe incidence of symptoms.	Change from Baseline NSI at 1 week after the intervention.
Primary	Neurobehavioral Symptom Inventory (NSI)	A measure of common post-concussive symptoms rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to more severe incidence of symptoms.	Change from Baseline NSI at 6 weeks after the intervention.
Primary	Neurobehavioral Symptom Inventory (NSI)	A measure of common post-concussive symptoms rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to more severe incidence of symptoms.	Change from 1 week post-intervention NSI at 6 weeks after the intervention.
Primary	Magnetic Resonance Imaging (MRI) w/out contrast (optional)	Medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. Mean white matter and CSF signals across time are calculated for each participant. Additionally, time courses for regions of interest are also extracted.	Change from Baseline MRI at 1 week after the intervention.
Secondary	NIH Toolbox Quality of Life Assessment (NeuroQoL)	Questionnaire to assess quality of life with regard to cognitive, social, emotional, and behavioral abilities rated on a 5-point Likert scale (1-5); with low scores corresponding to mild to no impairment in these abilities and high scores corresponding to more severe impairment in these abilities.	Change from Baseline NeuroQoL at 1 week after the intervention.
Secondary	NIH Toolbox Quality of Life Assessment (NeuroQoL)	Questionnaire to assess quality of life with regard to cognitive, social, emotional, and behavioral abilities rated on a 5-point Likert scale (1-5); with low scores corresponding to mild to no impairment in these abilities and high scores corresponding to more severe impairment in these abilities.	Change from Baseline NeuroQoL at 6 weeks after the intervention.
Secondary	NIH Toolbox Quality of Life Assessment (NeuroQoL)	Questionnaire to assess quality of life with regard to cognitive, social, emotional, and behavioral abilities rated on a 5-point Likert scale (1-5); with low scores corresponding to mild to no impairment in these abilities and high scores corresponding to more severe impairment in these abilities.	Change from 1 week post-intervention NeuroQoL at 6 weeks after the intervention.
Secondary	Insomnia Severity Index (ISI)	Measure of insomnia severity rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of insomnia and high scores corresponding to more severe incidences of insomnia.	Change from Baseline ISI at 1 week after the intervention.
Secondary	Insomnia Severity Index (ISI)	Measure of insomnia severity rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of insomnia and high scores corresponding to more severe incidences of insomnia.	Change from Baseline ISI at 6 weeks after the intervention.
Secondary	Insomnia Severity Index (ISI)	Measure of insomnia severity rated on a 5-point Likert scale (0-4); with low scores corresponding to mild or no incidence of insomnia and high scores corresponding to more severe incidences of insomnia.	Change from 1 week post-intervention ISI at 6 weeks after the intervention.
Secondary	Fusion Task	Multi-modal assessment of brain function including EEG and eye tracking. The EEG measures to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands. Other outcome measures to be assessed include saccadic response time latency, saccadic response time consistency, manual response time latency, manual response time consistency, and 1-back total score.	Change from Baseline Fusion task at 1 week after the intervention.
Secondary	Fusion Task	Multi-modal assessment of brain function including EEG and eye tracking. The EEG measures to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands. Other outcome measures to be assessed include saccadic response time latency, saccadic response time consistency, manual response time latency, manual response time consistency, and 1-back total score.	Change from Baseline Fusion task at 6 weeks after the intervention.
Secondary	Fusion Task	Multi-modal assessment of brain function including EEG and eye tracking. The EEG measures to be assessed include functional connectivity, mean ERP amplitude, and spectral power of delta, theta, alpha, beta, and gamma frequency bands. Other outcome measures to be assessed include saccadic response time latency, saccadic response time consistency, manual response time latency, manual response time consistency, and 1-back total score.	Change from 1 week post-intervention Fusion task at 6 weeks after the intervention.
Secondary	tDCS Symptom Rating Questionnaire (SRQ)	Questionnaire to assess pre-post tDCS symptom rating, rated on a 4-point Likert scale (0-3); with low scores corresponding to mild or no incidence of symptoms and high scores corresponding to severe incidence of symptoms.	Change from pre-intervention SRQ at post-intervention.
Secondary	BrainHQ Task Load Index (TLX)	Subjective workload assessment of level of effort, mental demand, frustration, and performance during cognitive training, rated on a 10-point Likert scale (1-10); with low scores corresponding to less effort or mental demand and high scores corresponding to more effort or mental demand.	Immediately after the intervention.